Selank
Selank is a synthetic heptapeptide studied primarily in Russian clinical literature for anxiety-related disorders. Human data exist, but they are small, geographically concentrated and do not validate the broader cognitive-enhancement claims common in biohacking culture.
Selank has shown a human signal for reducing anxiety and is increasingly used by the community to support a calmer, more focused mental state.
The strongest defensible story is anxiety—not generalized cognitive enhancement.
●●●○○
Small comparative clinical studies exist in anxiety-related populations.
●●●○○
Neuroactive hypotheses exist without broad clinical validation.
●●●○○
Interesting biology; uncertain translation.
●●●●○
Frequently discussed around “calm focus,” anxiety and subjective clarity.
A narrower evidence story than its reputation.
Selank is a seven-amino-acid synthetic peptide (TKPRPGP). Its clinical literature is centered on anxiolytic effects rather than broad cognitive enhancement.
Reduced anxiety can improve perceived concentration without demonstrating a direct nootropic effect.
There is a signal—but the evidence base is small.
A 2008 comparative study enrolled 62 patients with generalized anxiety disorder and neurasthenia: 30 received Selank and 32 medazepam. The authors reported similar anxiolytic effects, with additional antiasthenic and psychostimulant effects in the Selank group.
A later study compared phenazepam monotherapy in 30 patients with combined Selank plus phenazepam in 40 patients with anxiety-related disorders.
What it does not support: treating Selank as a broadly proven cognitive enhancer.
The community often turns anxiolysis into “nootropics.”
Public discussion frequently describes calmness, focus, reduced anxiety and clearer thinking.
Where the story gets stretched.
What people are actually reporting.
Selank community use is dominated by intranasal administration, with recurring discussion around short-term anxiety relief, calm focus and subjective mental clarity.
Lower and higher amounts both appear, and spray concentration varies widely between products. Some users report subcutaneous use at higher amounts, but intranasal use is the clearer community pattern.
Selank has human research, particularly around anxiety, but there is no FDA-established dosing regimen in the United States. The published clinical literature and community use are not equivalent evidence bases, and online spray products can differ substantially in concentration and formulation.
Human exposure exists. Important uncertainties remain.
FDA currently lists Selank acetate among bulk substances for which compounded products may pose immunogenicity risk for certain routes because of aggregation and peptide-related impurities, and states that it lacks important safety information regarding Selank acetate administered to humans.
Selank is not an FDA-approved drug. Compounded drugs are not FDA-approved or reviewed for safety, effectiveness or quality before marketing.
MEANINGFUL
This is not a case of “no human evidence.” It is a limited human anxiety signal being generalized into a much larger cognitive-enhancement narrative.
Primary sources behind the profile.
Put Selank in context.
Cognition
Separate anxiety, mood, subjective focus and objective cognition.
What the evidence actually shows.
Human anxiety signal is preliminary, not proof of broad cognitive enhancement
Two small comparative studies (60 and 62 participants) reported anxiety-related outcomes. Study size, setting, reporting limitations and the absence of large confirmatory trials restrict certainty. These findings do not establish improved memory, productivity, or sleep in healthy people.
Verification source: Medvedev et al., 2014 — comparative anxiety study (60 participants); Zozulia et al., 2008 — anxiety/neurasthenia study (62 participants).
Community Protocol Signal describes unvalidated practices and is not a clinical dosing recommendation.